Bcal Diagnostics Ltd
BCAL Diagnostics Limited, a screening and diagnostic company, engages in developing a novel blood screening test to improve the diagnosis and monitoring of breast cancer. It develops BREASTESTplus, a first-in-class blood test designed to be used alongside standard mammogram in breast cancer screening. The company also develops BREASTEST, BCAL Diagnostics, and BCAL Dx. The company was incorporated… Read more
Market Cap & Net Worth: Bcal Diagnostics Ltd (BDX)
Bcal Diagnostics Ltd (AU:BDX) has a market capitalization of $21.46 Million (AU$34.66 Million) as of March 18, 2026. Listed on the AU stock exchange, this Australia-based company holds position #28379 globally and #732 in its home market, demonstrating a -18.26% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Bcal Diagnostics Ltd's stock price AU$0.09 by its total outstanding shares 368683291 (368.68 Million).
Bcal Diagnostics Ltd Market Cap History: 2021 to 2026
Bcal Diagnostics Ltd's market capitalization history from 2021 to 2026. Data shows change from $28.54 Million to $21.46 Million (-18.94% CAGR).
Bcal Diagnostics Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Bcal Diagnostics Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
1023.41x
Bcal Diagnostics Ltd's market cap is 1023.41 times its annual revenue
0.69x
Higher than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $28.54 Million | $718.67K | -$3.39 Million | 39.71x | N/A |
| 2022 | $13.70 Million | $2.79 Million | -$5.06 Million | 4.91x | N/A |
| 2023 | $22.60 Million | $3.10 Million | -$6.40 Million | 7.29x | N/A |
| 2024 | $22.14 Million | $21.64K | -$7.24 Million | 1023.41x | N/A |
Competitor Companies of BDX by Market Capitalization
Companies near Bcal Diagnostics Ltd in the global market cap rankings as of March 18, 2026.
Key companies related to Bcal Diagnostics Ltd by market ranking:
- Thermo Fisher Scientific Inc (NYSE:TMO): Ranked #90 globally with a market cap of $177.20 Billion USD.
- Danaher Corporation (NYSE:DHR): Ranked #151 globally with a market cap of $122.79 Billion USD.
- IDEXX Laboratories Inc (NASDAQ:IDXX): Ranked #466 globally with a market cap of $46.38 Billion USD.
- Lonza Group Ltd (PINK:LZAGF): Ranked #511 globally with a market cap of $41.73 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #90 | Thermo Fisher Scientific Inc | NYSE:TMO | $177.20 Billion | $472.71 |
| #151 | Danaher Corporation | NYSE:DHR | $122.79 Billion | $195.21 |
| #466 | IDEXX Laboratories Inc | NASDAQ:IDXX | $46.38 Billion | $586.98 |
| #511 | Lonza Group Ltd | PINK:LZAGF | $41.73 Billion | $596.13 |
Bcal Diagnostics Ltd Historical Marketcap From 2021 to 2026
Between 2021 and today, Bcal Diagnostics Ltd's market cap moved from $28.54 Million to $ 21.46 Million, with a yearly change of -18.94%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | AU$21.46 Million | -10.48% |
| 2025 | AU$23.97 Million | +8.25% |
| 2024 | AU$22.14 Million | -2.02% |
| 2023 | AU$22.60 Million | +65.00% |
| 2022 | AU$13.70 Million | -52.00% |
| 2021 | AU$28.54 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Bcal Diagnostics Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $21.46 Million USD |
| MoneyControl | $21.46 Million USD |
| MarketWatch | $21.46 Million USD |
| marketcap.company | $21.46 Million USD |
| Reuters | $21.46 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.